SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study
16 references·2 citing·44 second hop
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study (2017)Efficacy and safety of agomelatine (10 or…The Diagnosis of and Treatment Recommendations for Anxiety Disorders (2014)The Diagnosis of and Treatmen…Agomelatine in Generalized Anxiety Disorder (2014)Agomelatine in Generalized An…GENERALIZABILITY OF CLINICAL TRIAL RESULTS FOR GENERALIZED ANXIETY DISORDER TO COMMUNITY SAMPLES (2012)GENERALIZABILITY OF CLINICAL …Agomelatine Prevents Relapse in Generalized Anxiety Disorder (2012)Agomelatine Prevents Relapse …The size and burden of mental disorders and other disorders of the brain in Europe 2010 (2011)The size and burden of mental…Single-Center Trials Show Larger Treatment Effects Than Multicenter Trials: Evidence From a Meta-epidemiologic Study (2011)Single-Center Trials Show Lar…Efficacy of Agomelatine in Generalized Anxiety Disorder (2008)Efficacy of Agomelatine in Ge…Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale (2008)Assessing treatment effects i…What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension (2006)What Clinical and Symptom Fea…Human and economic burden of generalized anxiety disorder (2006)Human and economic burden of …Antidepressants for generalised anxiety disorder (GAD) (2003)Antidepressants for generalis…The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 (1998)The Mini-International Neurop…The Hospital Anxiety and Depression Scale (1983)The Hospital Anxiety and Depr…A New Depression Scale Designed to be Sensitive to Change (1979)A New Depression Scale Design…ECDEU Assessment Manual for Psychopharmacology (1976)ECDEU Assessment Manual for P…THE ASSESSMENT OF ANXIETY STATES BY RATING (1959)THE ASSESSMENT OF ANXIETY STA…12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder (2018)12-week double-blind randomiz…Treatment of anxiety disorders (2017)Treatment of anxiety disordersEmpirical Evidence of Bias (1995)Empirical Evidence of Bias (1995)Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? (1998)Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials (2012)Influence of trial sample size on treatment effect estimates: meta-epidemiological study (2013)Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation (2015)The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. (1992)The MOS 36-ltem Short-Form Health Survey (SF-36) (1992)The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research (2009)The Use and Effectiveness of Mobile Apps for Depression: Results From a Fully Remote Clinical Trial (2016)Effects of Internet-Based Cognitive Behavioral Therapy in Routine Care for Adults in Treatment for Depression and Anxiety: Systematic Review and Meta-Analysis (2020)A 12-Item Short-Form Health Survey (1996)Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication (2005)Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis (2011)Psychometric Comparison of the Generalized Anxiety Disorder Scale-7 and the Penn State Worry Questionnaire for Measuring Response during Treatment of Generalised Anxiety Disorder (2011)The prefrontal cortex, pathological anxiety, and anxiety disorders (2021)A RATING SCALE FOR DEPRESSION (1960)Development of a Rating Scale for Primary Depressive Illness (1967)Diagnostic Criteria for Use in Psychiatric Research (1972)The PHQ-9: A New Depression Diagnostic and Severity Measure (2002)The validity of the Hospital Anxiety and Depression Scale (2002)Diagnostic and Statistical Manual of Mental Disorders (1988)The PHQ-9 (2001)Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States (2012)Diagnostic and Statistical Manual of Mental Disorders (2013)The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013 (2014)Epidemiology of anxiety disorders in the 21st century (2015)The detection of psychiatric illness by questionnaire (1973)Endogenomorphic Depression (1974)A scaled version of the General Health Questionnaire (1979)The Multidimensional Scale of Perceived Social Support (1988)The brief resilience scale: Assessing the ability to bounce back (2008)Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States (1994)Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication (2005)Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019)Anxiety Disorders (2022)An inventory for measuring clinical anxiety: Psychometric properties. (1988)Development and validation of the penn state worry questionnaire (1990)A Brief Measure for Assessing Generalized Anxiety Disorder (2006)The Yale-Brown Obsessive Compulsive Scale (1989)Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity (1997)Cognitive-Behavioral Therapy for Adult Anxiety Disorders (2008)Short screening scales to monitor population prevalences and trends in non-specific psychological distress (2002)Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. (2017)
this work references cited by second hop

References

  • 1983The Hospital Anxiety and Depression Scale47,171 cited
  • 1998The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-1019,258 cited
  • 1979A New Depression Scale Designed to be Sensitive to Change13,964 cited
  • 1959THE ASSESSMENT OF ANXIETY STATES BY RATING11,507 cited
  • 1976ECDEU Assessment Manual for Psychopharmacology8,900 cited
  • 2011The size and burden of mental disorders and other disorders of the brain in Europe 20103,749 cited
  • 2008Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale469 cited
  • 2006Human and economic burden of generalized anxiety disorder437 cited
  • 2011Single-Center Trials Show Larger Treatment Effects Than Multicenter Trials: Evidence From a Meta-epidemiologic Study305 cited
  • 2006What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension183 cited
  • 2008Efficacy of Agomelatine in Generalized Anxiety Disorder174 cited
  • 2003Antidepressants for generalised anxiety disorder (GAD)162 cited
  • 2014The Diagnosis of and Treatment Recommendations for Anxiety Disorders100 cited
  • 2012Agomelatine Prevents Relapse in Generalized Anxiety Disorder

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

94 cited
  • 2014Agomelatine in Generalized Anxiety Disorder67 cited
  • 2012GENERALIZABILITY OF CLINICAL TRIAL RESULTS FOR GENERALIZED ANXIETY DISORDER TO COMMUNITY SAMPLES61 cited
  • Cited by

    • 2017Treatment of anxiety disorders845 cited
    • 201812-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder32 cited